12,550 Shares in Harrow, Inc. (NASDAQ:HROW) Bought by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd acquired a new stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 12,550 shares of the company's stock, valued at approximately $421,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock worth $10,717,000 after purchasing an additional 194,480 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Harrow by 195.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company's stock worth $11,313,000 after acquiring an additional 166,602 shares during the last quarter. Trexquant Investment LP grew its stake in Harrow by 1,806.8% in the 4th quarter. Trexquant Investment LP now owns 94,500 shares of the company's stock worth $3,170,000 after acquiring an additional 89,544 shares during the period. Barclays PLC lifted its stake in shares of Harrow by 301.9% during the 3rd quarter. Barclays PLC now owns 52,593 shares of the company's stock worth $2,365,000 after purchasing an additional 39,506 shares during the period. Finally, Diametric Capital LP boosted its holdings in shares of Harrow by 49.0% during the fourth quarter. Diametric Capital LP now owns 110,295 shares of the company's stock worth $3,700,000 after purchasing an additional 36,269 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HROW. B. Riley reduced their target price on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. HC Wainwright reissued a "buy" rating and issued a $57.00 target price on shares of Harrow in a research report on Monday, March 31st.

Harrow Trading Up 0.8 %

Shares of NASDAQ HROW traded up $0.19 during midday trading on Monday, hitting $24.28. The stock had a trading volume of 41,002 shares, compared to its average volume of 508,457. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a 1-year low of $9.86 and a 1-year high of $59.23. The company has a market capitalization of $865.68 million, a price-to-earnings ratio of -25.83 and a beta of 0.46. The company has a fifty day moving average price of $26.87 and a 200 day moving average price of $36.30.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $66.83 million during the quarter, compared to the consensus estimate of $66.01 million. On average, analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.